Event Description:
Speakers:
Hosted by Scott Stout, CEO, MedVector
Rocio Salazar, Associate Director R&D Procurement, Study Procurement Partner
Jonathan Helfgott, Johns Hopkins University, President Association of Graduate Regulatory Educators, Former FDA Senior Leader
Chris Popple, CEO, Nexus Collaboration Partners
Brad Hightower, CEO, Hightower Clinical Research
Description
How can sites effectively leverage new diversity-focused rules and regulations to enhance trial efficiency and patient care? In this webinar, we will explore the opportunities for sites to collaborate with local HCPs, identify which protocol events can be delegated, and examine the impacts on essential documents like the 1572 and Delegation of Authority (DOA) log.
Hear from industry experts on how sites are adapting to these changes and how Sponsors are responding to this evolving model of trial execution. Whether you’re looking to expand your site’s capabilities or streamline your processes, this session will provide actionable insights to help you succeed in a decentralized trial environment.
Learning Objectives:
- Explore the impact of decentralized trial strategies on 1572 and DOA documentation.
- Implement best practices for integrating local HCPs into your site’s clinical trial operations.
- Evaluate Sponsor responses and adjust site strategies for decentralized trials.